Status | Study |
Active, not recruiting |
Study Name: Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Condition: Asthma Date: 2015-02-26 Interventions: Drug: Mepolizumab Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous a |
Completed |
Study Name: Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Condition: Asthma Date: 2014-10-30 Interventions: Biological: Mepolizumab Humani |
Active, not recruiting |
Study Name: A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Condition: Asthma Date: 2014-05-08 Interventions: Biological: Mepolizumab Mepoli |
Completed |
Study Name: Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Condition: Eosinophilic Asthma Date: 2012-01-03 Interventions: Drug: Reslizumab Reslizumab ad |
Completed |
Study Name: A Phase IIa Study of KHK4563 Condition: Uncontrolled and Suspected Eosinophilic Asthma Date: 2011-08-07 Interventions: Drug: KHK4563 every 4 weeks fo |
Completed |
Study Name: Efficacy, Safety, and Tolerability of SAR231893 (REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma Condition: Asthma Date: 2011-03-09 Interventions: Biological: SAR231893 (REGN668) |
Terminated |
Study Name: Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Condition: Eosinophilic Asthma Date: 2011-02-04 Interventions: Drug: Reslizumab Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 da |
Completed |
Study Name: A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Condition: Eosinophilic Asthma Date: 2011-01-28 Interventions: Drug: Reslizumab Patients were |
Completed |
Study Name: A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Condition: Eosinophilic Asthma Date: 2011-01-25 Interventions: Drug: Reslizumab Patients were |
Completed |
Study Name: A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Condition: Eosinophilic Asthma Date: 2010-12-29 Interventions: Drug: Reslizumab 3.0 mg/kg or |